Brief: Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
08/09/2025 13:42
Sept 8 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN DOSES FIRST EU PATIENT IN PHASE 3 PIVOTAL MIRACLE TRIAL FOR TREATMENT OF ACUTE MYELOID LEUKEMIA MOLECULIN BIOTECH INC: ON TRACK TO RECRUIT 45 SUBJECTS IN 4Q25 FOR INITIAL DATA UNBLINDING MOLECULIN BIOTECH INC: INITIAL DATA READOUT IS ON TRACK FOR H2 2025 Source text: ID:nGNX6TB7Sr Further company coverage: MBRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM